Brain molecule makes neurons less selective, deepening understanding of human cognition

Excitatory neurons from the brains of mice

Excitatory neurons from mice’s brains are depicted in green, and PV inhibitory neurons are pictured in magenta. Cells in the deep hippocampus, which helps navigate space, are represented toward the left side of the image. Toward the right side, cells are defined in the visual cortex. Findings from Johns Hopkins Medicine may help scientists better understand the causes of autism, schizophrenia and epilepsy.

Neuroscientists from Johns Hopkins Medicine say they have determined how a brain cell surface molecule shapes certain neurons’ behaviour.

The research, which was published on October 2 in Nature, reveals how a molecule called the calcium-permeable (CP)-AMPA receptor suppresses a specific neuron’s ability to pay attention to specific external cues, such as your friend’s earrings. The study was conducted on genetically engineered mice. Understanding why some neurons are less “selective” about their response to certain cues may also help researchers study conditions such as schizophrenia, epilepsy, and autism, which are marked by the faulty processing of external cues and misfirings of neurons in the mammalian brain.

“We have found that the calcium-permeable subtype of AMPA receptors plays an additional role in suppressing the selectivity of a specific neuron,” says Dr. Ingie Hong, the first author and a neuroscience instructor at Johns Hopkins University School of Medicine. “Until now, the function of these particular receptors in the broader mammalian brain during everyday activities has been a mystery.”

AMPA receptors are critical to the fast transfer of information and memory formation in the brain, such as hearing and remembering a person’s name. The subtype of AMPA receptors in this study, CP-AMPA receptors, act as a “gate” that lowers the selectivity of parvalbumin (PV) neurons, which are inhibitory and thereby cast unselective inhibition to nearby neurons, the researchers say.

“Selective neurons will respond to something really specific, for example, your grandfather’s mustache, whereas less selective neurons will respond to different faces or people as well,” Hong says. “We’ve been looking for the mechanisms and molecules that control this specificity, or selectivity, and how it goes awry in conditions such as autism and epilepsy, where excitatory neurons can become overstimulated.”   

The researchers also found that mutations of GluA2, a protein subunit within the CP-AMPA receptor, are associated with intellectual disabilities.

“Human mutations in the GluA2 subunit of the AMPA receptors, which regulates the calcium permeability of the receptor, can lead to intellectual disability and autism,” says senior author Huganir. “This suggests tight control of AMPA receptor calcium permeability is essential for human cognition.”

Specifically, the investigators focused on CP-AMPA receptors in two distinct areas of the brain, the visual cortex, where neurons process visual information, and the hippocampus, where neurons respond to “where you are, where you are headed, or where you have been,” Hong says.

To conduct their research, the scientists developed novel adeno-associated virus vectors to replace calcium permeable AMPA receptors with impermeable counterparts and express them in the mouse brain. They say they hope these vectors can help treat disorders that arise from AMPA receptor mutations in the future.

To map out PV neuron selectivity, the scientists used advanced imaging techniques to observe neuron structure and activity deep within genetically engineered mice brains while showing them video stimuli.

“In most cases, we found that these PV neurons, which are typically less selective, became more selective to visual stimuli as well as spatial location when we swapped out CP-AMPA receptors for impermeable molecules, making inhibitory neurons act more like excitatory neurons,” Hong says.

The researchers say the high amount of CP-AMPA receptors in PV neurons is well-conserved across many species of mammals, including humans.

“Making neuron inhibition less selective makes our neural circuits more efficient than species that don’t have this molecular feature,” Hong says. “It probably also means that our neural networks are more stable.”

Hong says the new research may also have implications for machine learning used in artificial intelligence.

“In machine learning, there are many computerized ‘artificial’ neurons that are trained to be very selective or less selective,” he says. “We’re trying to find how specific and less specific units can work together to give us smarter machines and smarter AI.”

Credit David Cheon and Ingie Hong

Some diabetes drugs tied to lower risk of dementia, Parkinson’s disease

A randomized, controlled trial led by Mass General Brigham researchers demonstrates that cognitive behavioral therapy can significantly reduce the impact of fibromyalgia pain

A study suggests that a certain class of drugs used to treat diabetes may be linked to a reduced risk of dementia and Parkinson’s disease.

The study examined SGLT2 inhibitors, also known as gliflozins, which lower blood sugar by prompting the kidneys to excrete sugar through urine.

“We are aware that neurodegenerative diseases such as dementia and Parkinson’s disease are becoming more prevalent as the population ages. People with diabetes are at a higher risk of cognitive impairment. It is encouraging to see that this category of drugs may offer some protection against dementia and Parkinson’s disease,” stated study author Minyoung Lee, MD, PhD, from Yonsei University College of Medicine in Seoul, South Korea.

The retrospective study examined individuals with type 2 diabetes who initiated diabetes medication from 2014 to 2019 in South Korea. Individuals using SGLT2 inhibitors were compared with those using other oral diabetes drugs, ensuring that the two groups had similar ages, other health conditions, and diabetes-related complications. The researchers then monitored the participants to determine whether they developed dementia or Parkinson’s disease. The individuals taking SGLT2 inhibitors were monitored for an average of two years, while those taking the other drugs were monitored for an average of four years.

Among the 358,862 participants with an average age of 58, 6,837 people developed dementia or Parkinson’s disease during the study. For Alzheimer’s disease, the incidence rate for people taking SGLT2 inhibitors was 39.7 cases per 10,000 person-years, compared to 63.7 cases for those taking other diabetes drugs. Person-years represent both the number of people in the study and the amount of time each person spends in the study. For vascular dementia, which is dementia caused by vascular disease, the incidence rate for people taking the SGLT2 drugs was 10.6 cases per 10,000, compared to 18.7 for those taking the other drugs. For Parkinson’s disease, the incidence rate for those taking the SGLT2 drugs was 9.3 cases per 10,000, compared to 13.7 for those taking the other drugs. After researchers adjusted for other factors that could affect the risk of dementia or Parkinson’s disease, such as complications from diabetes and medications, they found that SGLT2 inhibitor use was associated with a 20% reduced risk of Alzheimer’s disease and a 20% reduced risk of Parkinson’s disease. Those taking the drugs had a 30% reduced risk of developing vascular dementia.

Adding beans and pulses can lead a higher diet quality

When People Add One Cup of Beans and/or Chickpeas daily to their diet, diet quality improves.

Diet quality improves when people add one cup of Beans and/or Chickpeas daily. Credit Coalition for the Advancement of Pulses

New research shows an association between more excellent beans and pulse consumption, improved shortfall nutrient intakes, and higher diet quality in American adults.

Researchers assessed the effect of increased bean and pulse consumption in the typical US dietary pattern on shortfall nutrient intakes and diet quality outcomes. According to the findings, nutritional patterns rich in beans and pulses are associated with significantly higher diet quality scores and greater intake of shortfall nutrients, including nutrients of public health concern. Pulses are the edible seeds of plants in the legume family.  Pulses grow in pods and come in various shapes, sizes, and colours. They include beans, peas, chickpeas, and lentils.  The composite included canned and dried kidney beans, black beans, chickpeas, and pinto beans for this study. 

Impact on Shortfall Nutrients

Using data from the National Health and Nutrition Examination Survey, 2001-2018, the analyses modelled the addition of one and two servings of beans (as outlined above) in adults. Results show that greater consumption of beans is associated with significant increases in several shortfall nutrients, including dietary fibre, potassium, magnesium, iron, folate, and choline.

Impact on Diet Quality

Additionally, the addition of 1 and 2 servings of beans daily to the typical US dietary pattern significantly increased overall diet quality, as assessed by USDA’s Healthy Eating Index-2015 (HEI-2015). In fact, HEI-2015 total scores were 15% greater with an additional serving of beans and 19% higher with two servings of beans relative to the typical US dietary pattern.

This evaluation showed that beans substantially increased daily dietary fibre intake in both younger and older adults.  This is critical since fewer than 1 in 10 US adults meet fibre recommendations to maintain optimal digestive health and prevent chronic diseases, including cardiovascular disease, diabetes, obesity and certain cancers.  Additionally, the majority of US adults fall short of meeting potassium recommendations.  According to the American Heart Association, “Foods with potassium can help control blood pressure by blunting the effects of sodium, and the more potassium you eat, the more sodium you process out of the body.”

“This research clearly shows that eating beans and pulses is good, but eating more is better.,” states study author Yanni Papanikolaou of Nutritional Strategies Inc.  “Beans and pulses are excellent sources of fibre, folate and potassium and excellent sources of plant protein that also provides iron and zinc like other protein foods.”

New study finds a promising combined therapy for multiple sclerosis

The authors of the study, from left to right: Esteban Ballestar (IJC), Cristina Ramo-Tello (IGTP), Federico Fondelli (IJC-IGTP), Eva Martínez-Cáceres (IGTP) and Jana Willemyns (IGTP)

The authors of the study, from left to right: Esteban Ballestar (IJC), Cristina Ramo-Tello (IGTP), Federico Fondelli (IJC-IGTP), Eva Martínez-Cáceres (IGTP) and Jana Willemyns (IGTP) Credit Josep Carreras Leukaemia Research Institute

Multiple Sclerosis (MS) is a chronic disease in which the immune system mistakenly attacks the protective layer around nerve cells, known as the myelin sheath. This results in nerve damage and increasing disability. Current treatments, such as immunosuppressants, help reduce these harmful attacks but also weaken the overall immune system, leaving patients susceptible to infections and cancer. Scientists are now investigating a more targeted therapy using special immune cells, called tolerogenic dendritic cells (tolDCs), from the same patients.

TolDCs can restore immune balance without affecting the body’s natural defences. However, since a hallmark of MS is precisely immune system dysfunction, these cells’ effectiveness for autotransplantation might be compromised. Therefore, it is essential to better understand how the disease affects the starting material for this cellular therapy before it can be applied.

In a study published in the prestigious Journal of Clinical Investigation, researchers examined CD14+ monocytes, mature dendritic cells (mDCs), and Vitamin D3-treated tolerogenic dendritic cells (VitD3-tolDCs) from MS patients who had not yet received treatment, as well as from healthy individuals. These cells are loaded with myelin antigens to help “teach” the immune system to stop attacking the nervous system. This approach is groundbreaking as it uses a patient’s own immune cells, modified to induce immune tolerance, in an effort to treat the autoimmune nature of MS.

The research, conducted by Dr. Eva Martinez-Cáceres and Dr. Esteban Ballestar from the Josep Carreras Institute, with Federico Fondelli as the lead author, discovered that immune cells from MS patients (specifically monocytes, which are precursors of tolDCs) maintain a “pro-inflammatory” signature even after being transformed into VitD3-tolDCs, the therapeutic cell type used in treatment. This signature reduces the effectiveness of these cells compared to those derived from healthy individuals, resulting in them not fully realizing their potential benefits.

Using advanced research methods, the researchers discovered a pathway called the Aryl Hydrocarbon Receptor (AhR) that is associated with this changed immune response. By using a drug that affects AhR, the team was able to restore the normal function of VitD3-tolDCs from MS patients in a lab setting. Interestingly, they found that Dimethyl Fumarate, an approved MS drug, had a similar effect to AhR modulation and restored the cells’ full effectiveness with a safer toxic profile.

Finally, studies in MS animal models showed that a combination of VitD3-tolDCs and Dimethyl Fumarate led to better results than using either treatment alone. This combination therapy significantly reduced symptoms in mice, suggesting enhanced potential for treating human patients.

Reducing daily sitting may prevent back pain

Walkable neighborhoods may pave way to less cardiovascular risk
A new study from the University of Turku in Finland showed that reducing daily sitting prevented back pain from worsening over six months. The result strengthens the current understanding of the link between activity and back pain and the mechanisms related to back pain.

The study from the Turku PET Centre and UKK Institute in Finland looked into whether reducing daily sitting could help prevent or relieve back pain in overweight or obese adults who spend most of their day sitting. The participants were able to reduce their sitting time by an average of 40 minutes per day over the six-month study period.“Our participants were quite normal middle-aged adults, who sat a great deal, exercised little, and had gained some extra weight. These factors increase the risk for cardiovascular disease and back pain,” says Doctoral Researcher and Physiotherapist Jooa Norha from the University of Turku in Finland.
Previous results from the same and other research groups have suggested that sitting may be detrimental to back health, but the data has been preliminary.

Robust methods for studying the mechanisms behind back pain
The researchers also examined potential mechanisms behind the prevention of back pain.
”However, we did not observe that the changes in back pain were related to changes in the fattiness or glucose metabolism of the back muscles,” Norha says.
Individuals with back pain have excessive fat deposits within the back muscles, and impaired glucose metabolism or insulin sensitivity can predispose to pain. Nevertheless, back pain can be prevented or relieved even if no improvements in muscle composition or metabolism occur. The researchers measured the back muscles using magnetic resonance imaging (MRI) and PET imaging based on a radioactive tracer.
“If you have a tendency for back pain or excessive sitting and are concerned for your back health, you can try to figure out ways to reduce sitting at work or during leisure time. However, it is important to note that physical activity, such as walking or more brisk exercise, is better than simply standing up,” Norha points out.
The researchers wish to remind us that switching between postures is more important than seeking the perfect posture.